Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate

2001 ◽  
Vol 28 (4M) ◽  
pp. 8-15 ◽  
Author(s):  
William Berry ◽  
Shaker Dakhil ◽  
Mary A. Gregurich ◽  
Lina Asmar
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Single Agent ◽  
Metastatic Carcinoma ◽  
Carcinoma Of The Prostate ◽  
Weekly Docetaxel ◽  
Hormone Refractory

Phase II trial of weekly docetaxel, zoledronic acid and selenium for hormone refractory prostate cancer

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 16113-16113
Author(s):  
J. G. Kattan ◽  
M. Ghosn ◽  
G. Chahine ◽  
A. Saroufim ◽  
F. Nasr ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Hormone Refractory Prostate Cancer ◽  
Weekly Docetaxel ◽  
Hormone Refractory

scholarly journals Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the eastern cooperative oncology group

Cancer ◽  
1993 ◽  
Vol 72 (8) ◽  
pp. 2457-2460 ◽  
Author(s):  
Bruce J. Roth ◽  
Patrick J. Loehrer ◽  
Beow Yong Yeap ◽  
George Wilding ◽  
Basil Kasimis ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Eastern Cooperative Oncology Group ◽  
Oncology Group ◽  
Carcinoma Of The Prostate ◽  
Hormone Refractory

scholarly journals Phase II trial of tamoxifen in metastatic carcinoma of the prostate

Cancer ◽  
1982 ◽  
Vol 49 (7) ◽  
pp. 1367-1372 ◽  
Author(s):  
John H. Glick ◽  
Alan Wein ◽  
Kristin Padavic ◽  
William Negendank ◽  
David Harris ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Carcinoma ◽  
Carcinoma Of The Prostate

Phase II trial of 5-fluorouracil and alpha-2b interferon in patients with hormone-refractory metastatic prostate cancer

Urology ◽  
1994 ◽  
Vol 44 (3) ◽  
pp. 377-380 ◽  
Author(s):  
Robert Dreicer ◽  
Paula Kforest ◽  
Richard D. Williams
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Metastatic Prostate Cancer ◽  
Phase Ii Trial ◽  
Hormone Refractory

Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non–Small-Cell Lung Cancer

2011 ◽  
Vol 29 (18) ◽  
pp. 2582-2589 ◽  
Author(s):  
David R. Spigel ◽  
Howard A. Burris ◽  
F. Anthony Greco ◽  
Dianna L. Shipley ◽  
Elke K. Friedman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Group Performance ◽  
Phase Ii Trial ◽  
Single Agent ◽  
Eastern Cooperative Oncology Group ◽  
Small Cell ◽  
Small Cell Lung

Purpose Sorafenib, an oral multikinase inhibitor, has shown preliminary activity in non–small-cell lung cancer (NSCLC). Patients with advanced NSCLC were treated with erlotinib with or without sorafenib in this multicenter phase II trial. Patients and Methods Key eligibility criteria included the following: stage IIIB or IV NSCLC; one to two prior regimens; Eastern Cooperative Oncology Group performance status of 0 to 2; and measurable disease. Patients were randomly assigned 2:1 to sorafenib (400 mg orally twice a day) plus erlotinib (150 mg orally daily) or placebo plus erlotinib and stratified by squamous/nonsquamous histology and prior bevacizumab. Treatment efficacy, measured by progression-free survival (PFS) and overall response rate (ORR), was compared. Treatment of 168 patients allowed detection of 40% improvement in the historical PFS of 2.2 months with single-agent erlotinib. Results One hundred sixty-eight patients enrolled from February 2008 to February 2009. Clinical characteristics of the two groups were similar. ORRs for sorafenib/erlotinib and placebo/erlotinib were 8% and 11%, respectively (P = .56); disease control rates were 54% and 38%, respectively (P = .056). Median PFS was 3.38 months for sorafenib/erlotinib versus 1.94 months for placebo/erlotinib (hazard ratio, 0.86; 95% CI, 0.60 to 1.22; P = .196). Seventy-two patients consented to analyses of tumor epidermal growth factor receptor (EGFR). In 67 patients with EGFR wild-type (WT) tumors, median PFS was 3.38 months for sorafenib/erlotinib versus 1.77 months for placebo/erlotinib (P = .018); median overall survival (OS) was 8 months for sorafenib/erlotinib versus 4.5 months for placebo/erlotinib (P = .019). An OS advantage for sorafenib/erlotinib was suggested among 43 patients with fluorescent in situ hybridization (FISH) EGFR-negative tumors (P = .064). Both regimens were tolerable, with modest toxicity increase with sorafenib. Conclusion Although there was little difference in ORR or PFS, subset analyses in EGFR WT and EGFR FISH–negative patients suggest a benefit for the combination of erlotinib/sorafenib compared with single-agent erlotinib with respect to PFS and OS.

Sign in / Sign up

Export Citation Format

Share Document